TNF Pharmaceuticals, Inc.
TNFA
$0.0642
-$0.0109-14.51%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -31.56% | -41.58% | -45.80% | -42.09% | -58.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.62% | -11.23% | -55.41% | -52.49% | -67.81% |
| Operating Income | -0.62% | 11.23% | 55.41% | 52.49% | 67.81% |
| Income Before Tax | 81.22% | 88.52% | 12.66% | -147.72% | -129.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 81.22% | 88.52% | 12.66% | -147.72% | -129.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.22% | 88.52% | 12.66% | -147.72% | -129.52% |
| EBIT | -0.62% | 11.23% | 55.41% | 52.49% | 67.81% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 96.11% | 92.95% | 59.85% | -160.18% | -41.21% |
| Normalized Basic EPS | 97.28% | 95.40% | 45.42% | -131.24% | -42.36% |
| EPS Diluted | 96.11% | 92.95% | 59.90% | -400.00% | -41.21% |
| Normalized Diluted EPS | 97.28% | 95.40% | 45.42% | -256.12% | -42.36% |
| Average Basic Shares Outstanding | 589.85% | 149.86% | 59.66% | 54.39% | 61.28% |
| Average Diluted Shares Outstanding | 589.85% | 149.86% | 59.66% | -69.11% | 61.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -0.07% | -- | -- |